Cargando…
P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS
Autores principales: | Duminuco, Andrea, Nardo, Antonella, Orofino, Alessandra, Romano, Alessandra, Figuera, Amalia Stefania, Chiarenza, Annalisa, Markovic, Uros, Caruso, Laura, Giunta, Giuliana, Leotta, Salvatore, Milone, Giuseppe, Cupri, Alessandra, Conticello, Concetta, Fabro, Vittorio Del, Mauro, Elisa, Maugeri, Cinzia, Vetro, Calogero, Parisi, Marina, Raimondo, Francesco DI, Palumbo, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430325/ http://dx.doi.org/10.1097/01.HS9.0000973108.49863.33 |
Ejemplares similares
-
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023) -
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology
por: Milone, Giuseppe, et al.
Publicado: (2022) -
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience
por: Duminuco, Andrea, et al.
Publicado: (2023) -
Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022) -
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
por: Duminuco, Andrea, et al.
Publicado: (2023)